Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation.

Adult Animals Cell Line Cohort Studies Disease Models, Animal Female Fibroblast Growth Factor-23 Fibroblast Growth Factors / blood Humans Inflammatory Bowel Diseases / blood Interleukin-10 / deficiency Kidney / immunology Male Mice Mice, Transgenic Middle Aged Nuclear Receptor Subfamily 4, Group A, Member 2 / metabolism Primary Cell Culture Renal Insufficiency, Chronic / blood Tumor Necrosis Factor-alpha / blood
bone chronic kidney disease (CKD) cytokine fibroblast growth factor 23 (FGF23) inflammation inflammatory bowel disease tumor necrosis factor (TNF)

Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
10 2019
Historique:
received: 16 07 2018
revised: 11 03 2019
accepted: 05 04 2019
pubmed: 16 7 2019
medline: 21 10 2020
entrez: 15 7 2019
Statut: ppublish

Résumé

Fibroblast growth factor 23 (FGF23) regulates phosphate homeostasis, and its early rise in patients with chronic kidney disease is independently associated with all-cause mortality. Since inflammation is characteristic of chronic kidney disease and associates with increased plasma FGF23 we examined whether inflammation directly stimulates FGF23. In a population-based cohort, plasma tumor necrosis factor (TNF) was the only inflammatory cytokine that independently and positively correlated with plasma FGF23. Mouse models of chronic kidney disease showed signs of renal inflammation, renal FGF23 expression and elevated systemic FGF23 levels. Renal FGF23 expression coincided with expression of the orphan nuclear receptor Nurr1 regulating FGF23 in other organs. Antibody-mediated neutralization of TNF normalized plasma FGF23 and suppressed ectopic renal Fgf23 expression. Conversely, TNF administration to control mice increased plasma FGF23 without altering plasma phosphate. Moreover, in Il10-deficient mice with inflammatory bowel disease and normal kidney function, plasma FGF23 was elevated and normalized upon TNF neutralization. Thus, the inflammatory cytokine TNF contributes to elevated systemic FGF23 levels and also triggers ectopic renal Fgf23 expression in animal models of chronic kidney disease.

Identifiants

DOI: 10.1016/j.kint.2019.04.009 PMID: 31301888
pubmed: 31301888
pii: S0085-2538(19)30465-X
doi: 10.1016/j.kint.2019.04.009
pii:
doi:

Substances chimiques

FGF23 protein, human 0
Fgf23 protein, mouse 0
IL10 protein, mouse 0
Nr4a2 protein, mouse 0
Nuclear Receptor Subfamily 4, Group A, Member 2 0
TNF protein, human 0
Tnf protein, mouse 0
Tumor Necrosis Factor-alpha 0
Interleukin-10 130068-27-8
Fibroblast Growth Factors 62031-54-3
Fibroblast Growth Factor-23 7Q7P4S7RRE

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

890-905

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Auteurs

Daniela Egli-Spichtig (D)

Institute of Physiology, University of Zurich, Zurich, Switzerland; Swiss National Center of Competence in Research NCCR-Kidney.CH, University of Zurich, Zurich, Switzerland; Department of Pediatrics, Division of Nephrology, University of California, San Francisco, San Francisco, California, USA.

Pedro Henrique Imenez Silva (PH)

Institute of Physiology, University of Zurich, Zurich, Switzerland; Swiss National Center of Competence in Research NCCR-Kidney.CH, University of Zurich, Zurich, Switzerland.

Bob Glaudemans (B)

Institute of Physiology, University of Zurich, Zurich, Switzerland; Swiss National Center of Competence in Research NCCR-Kidney.CH, University of Zurich, Zurich, Switzerland.

Nicole Gehring (N)

Institute of Physiology, University of Zurich, Zurich, Switzerland; Swiss National Center of Competence in Research NCCR-Kidney.CH, University of Zurich, Zurich, Switzerland.

Carla Bettoni (C)

Institute of Physiology, University of Zurich, Zurich, Switzerland; Swiss National Center of Competence in Research NCCR-Kidney.CH, University of Zurich, Zurich, Switzerland.

Martin Y H Zhang (MYH)

Department of Pediatrics, Division of Nephrology, University of California, San Francisco, San Francisco, California, USA.

Eva M Pastor-Arroyo (EM)

Institute of Physiology, University of Zurich, Zurich, Switzerland; Swiss National Center of Competence in Research NCCR-Kidney.CH, University of Zurich, Zurich, Switzerland.

Désirée Schönenberger (D)

Institute of Physiology, University of Zurich, Zurich, Switzerland; Swiss National Center of Competence in Research NCCR-Kidney.CH, University of Zurich, Zurich, Switzerland.

Michal Rajski (M)

Institute of Physiology, University of Zurich, Zurich, Switzerland; Swiss National Center of Competence in Research NCCR-Kidney.CH, University of Zurich, Zurich, Switzerland.

David Hoogewijs (D)

Institute of Physiology, University of Zurich, Zurich, Switzerland; Swiss National Center of Competence in Research NCCR-Kidney.CH, University of Zurich, Zurich, Switzerland.

Felix Knauf (F)

Division of Nephrology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Benjamin Misselwitz (B)

University Hospital Zurich, Clinic for Gastroenterology and Hepatology, Zurich, Switzerland.

Isabelle Frey-Wagner (I)

University Hospital Zurich, Clinic for Gastroenterology and Hepatology, Zurich, Switzerland.

Gerhard Rogler (G)

University Hospital Zurich, Clinic for Gastroenterology and Hepatology, Zurich, Switzerland.

Daniel Ackermann (D)

Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Belen Ponte (B)

Department of Nephrology, University Hospital of Geneva (HUG), Geneva, Switzerland.

Menno Pruijm (M)

Department of Nephrology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Alexander Leichtle (A)

Institute of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Georg-Martin Fiedler (GM)

Institute of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Murielle Bochud (M)

Swiss National Center of Competence in Research NCCR-Kidney.CH, University of Zurich, Zurich, Switzerland; Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Virginia Ballotta (V)

Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, The Netherlands.

Sandra Hofmann (S)

Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, The Netherlands.

Farzana Perwad (F)

Department of Pediatrics, Division of Nephrology, University of California, San Francisco, San Francisco, California, USA.

Michael Föller (M)

Institute of Physiology, University of Hohenheim, Stuttgart, Germany.

Florian Lang (F)

Institute of Physiology I, University of Tübingen, Tübingen, Germany.

Roland H Wenger (RH)

Institute of Physiology, University of Zurich, Zurich, Switzerland; Swiss National Center of Competence in Research NCCR-Kidney.CH, University of Zurich, Zurich, Switzerland.

Ian Frew (I)

Institute of Physiology, University of Zurich, Zurich, Switzerland; Swiss National Center of Competence in Research NCCR-Kidney.CH, University of Zurich, Zurich, Switzerland.

Carsten A Wagner (CA)

Institute of Physiology, University of Zurich, Zurich, Switzerland; Swiss National Center of Competence in Research NCCR-Kidney.CH, University of Zurich, Zurich, Switzerland. Electronic address: Wagnerca@access.uzh.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Tumor necrosis factor stimulates fibroblast...
questionsmedicales.fr › Eucaryotes › Animaux › Tumor necrosis factor stimulates fibroblast...
questionsmedicales.fr › Cellules › Cellules cultivées › Lignée cellulaire › Tumor necrosis factor stimulates fibroblast...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Tumor necrosis factor stimulates fibroblast...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Tumor necrosis factor stimulates fibroblast...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Facteur-23 de croissance des fibroblastes › Tumor necrosis factor stimulates fibroblast...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Facteurs de croissance fibroblastique › Tumor necrosis factor stimulates fibroblast...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Tumor necrosis factor stimulates fibroblast...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies inflammatoires intestinales › Tumor necrosis factor stimulates fibroblast...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interleukines › Interleukine-10 › Tumor necrosis factor stimulates fibroblast...
questionsmedicales.fr › Appareil urogénital › Voies urinaires › Rein › Tumor necrosis factor stimulates fibroblast...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Tumor necrosis factor stimulates fibroblast...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souris transgéniques › Tumor necrosis factor stimulates fibroblast...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Tumor necrosis factor stimulates fibroblast...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Récepteurs cytoplasmiques et nucléaires › Membre-2 du groupe A de la sous-famille-4 de récepteurs nucléaires › Tumor necrosis factor stimulates fibroblast...
questionsmedicales.fr › Techniques d'investigation › Techniques in vitro › Techniques de culture › Techniques de culture cellulaire › Culture de cellules primaires › Tumor necrosis factor stimulates fibroblast...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Insuffisance rénale chronique › Tumor necrosis factor stimulates fibroblast...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Facteurs de nécrose tumorale › Facteur de nécrose tumorale alpha › Tumor necrosis factor stimulates fibroblast...